Spesolimab (BI 655130)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Spesolimab (BI 655130), covering 2023-12-14 to 2023-12-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis [Phase 2]